Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) has announced a stronger cash position heading into the third quarter of the year as the company’s focus remains on trials of its leukaemia drug.
Fundraising in late June left Faron with €12.8 million heading into the third quarter, with cash having sat at €6.3 million at the half-year stage, down from €9.9 million last year.
Focus remains on the development and upcoming phase two clinical trial of bexmarilimab, expected to start in the fourth quarter of this year, Faron said in its results statement.
The prospective acute myeloid leukaemia treatment was granted orphan drug designation on Tuesday, offering Faron exemption from application fees, tax credits for clinical trials and market exclusivity if the drug is ultimately approved.
“The recent US Food and Drug Administration orphan drug designation for bexmarilimab further reaffirms our program by offering important clinical development and commercialization benefits,” chief executive Markku Jalkanen said.
Faron’s losses for the first six months of the year climbed 4.5% to €13.7 million meanwhile, while per-share losses eased from €0.25 to €0.22.